How have RENE shares performed in 2024?

Cartesian Growth Co. II's stock was trading at $10.94 at the beginning of 2024. Since then, RENE shares have increased by 2.2% and is now trading at $11.18. View the best growth stocks for 2024 here .

What ETFs hold Cartesian Growth Co. II's stock?

ETFs with the largest weight of Cartesian Growth Co. II (NASDAQ:RENE) stock in their portfolio include Horizon Kinetics SPAC Active ETF (SPAQ) . CrossingBridge Pre-Merger SPAC ETF (SPC) .

Who are Cartesian Growth Co. II's major shareholders?

Cartesian Growth Co. II's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wealthspring Capital LLC (1.71%).

How do I buy shares of Cartesian Growth Co. II?

Shares of RENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RENE

Cartesian Growth Co. II (RENE) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free RENE Stock Alerts

$11.18

-0.01 (-0.09%)

(As of 04/19/2024 ET)

Compare

Today's Range: $11.18
▼
$11.19
50-Day Range: $11.04
▼
$11.19
52-Week Range: $10.52
▼
$11.92

Volume: 95,585 shs
Average Volume: 57,729 shs
Market Capitalization: $241.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Ownership SEC Filings Short Interest Social Media

Get Cartesian Growth Co. II alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Cartesian Growth Co. II Stock (NASDAQ:RENE)

Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York.

RENE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RENE Stock News Headlines

April 19, 2024 | americanbankingnews.com

Cartesian Growth Co. II (NASDAQ:RENE) Shares Up 0%

See More Headlines

Receive RENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cartesian Growth Co. II and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Unclassified
Industry: Holding & other investment offices
Sub-Industry: N/A
Current Symbol: NASDAQ:RENE
CUSIP: N/A
CIK: 1889112
Web: www.cartesiangrowth.com
Phone: 212-461-6363
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $11.44 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -65.59%
Return on Assets: 5.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.22
Quick Ratio: 0.22

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: $0.40 per share
Price / Cash Flow: 28.09
Book Value: ($0.64) per share
Price / Book: -17.47

Miscellaneous

Outstanding Shares: 21,620,000
Free Float: 17,297,000
Market Cap: $241.71 million
Optionable: Not Optionable
Beta: -0.01

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Peter Michael Yu Ph.D. (Age 63)
Chairman & CEO
Ms. Beth S. Michelson CFA (Age 54)
CFO & Director
Mr. Paul Seungpyo Hong Esq. (Age 54)
J.D., Senior Managing Director
Mr. Gregory R. Armstrong (Age 46)
Senior Managing Director

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RENE Stock Analysis - Frequently Asked Questions

How have RENE shares performed in 2024?: Cartesian Growth Co. II's stock was trading at $10.94 at the beginning of 2024. Since then, RENE shares have increased by 2.2% and is now trading at $11.18.
View the best growth stocks for 2024 here.
What ETFs hold Cartesian Growth Co. II's stock?: ETFs with the largest weight of Cartesian Growth Co. II (NASDAQ:RENE) stock in their portfolio include Horizon Kinetics SPAC Active ETF (SPAQ).CrossingBridge Pre-Merger SPAC ETF (SPC).
Who are Cartesian Growth Co. II's major shareholders?: Cartesian Growth Co. II's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wealthspring Capital LLC (1.71%).
How do I buy shares of Cartesian Growth Co. II?: Shares of RENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RENE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial